FLGT Earnings & Financial Statements
Fulgent Genetics, Inc.
$21.19
+$0.18(+0.86%)
57
Overall
60
Value
66
Tech
47
Quality
Market Cap
$578.10M
Volume
9.59K
52W Range
$13.46 - $31.04
Target Price
$19.00
FLGT earnings and financial statements: Fulgent Genetics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
FLGT Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $322.67M | $283.47M | $289.21M | $618.97M | $992.58M |
| Cost of revenue | $191.80M | $176.25M | $184.76M | $252.07M | $215.53M |
| Operating income | -$91.10M | -$73.92M | -$195.53M | $178.53M | $675.95M |
| EBITDA | -$44.06M | -$23.44M | -$141.04M | $216.69M | $686.96M |
| Net income | -$60.51M | -$42.71M | -$167.82M | $143.40M | $507.36M |
| EPS (diluted) | $-1.97 | $-1.41 | $-5.63 | $4.63 | $16.38 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.21B | $1.22B | $1.24B | $1.39B | $1.28B |
| Total liabilities | $106.81M | $90.81M | $102.04M | $116.18M | $112.84M |
| Shareholders’ equity | $1.11B | $1.13B | $1.14B | $1.27B | $1.16B |
| Cash and equivalents | $50.19M | $55.14M | $97.47M | $79.51M | $164.89M |
| Long-term debt | - | $6.61M | - | - | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$101.64M | $21.06M | $27.00M | $253.52M | $538.58M |
| Capital expenditure | -$22.57M | -$40.00M | -$22.21M | -$18.77M | -$23.84M |
| Free cash flow | -$124.21M | -$19.25M | $4.80M | $234.75M | $514.73M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | FLGT | $21.19 | +0.9% | 9.59K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |